Bellevue Group’s Teladoc Health TDOC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-272,798
| Closed | -$2.67M | – | 173 |
|
|
2024
Q2 | $2.67M | Hold |
272,798
| – | – | 0.04% | 108 |
|
|
2024
Q1 | $4.12M | Buy |
272,798
+13,394
| +5% | +$243K | 0.06% | 100 |
|
|
2023
Q4 | $5.59M | Sell |
259,404
-96,245
| -27% | -$1.78M | 0.09% | 93 |
|
|
2023
Q3 | $6.61M | Sell |
355,649
-36,615
| -9% | -$855K | 0.11% | 97 |
|
|
2023
Q2 | $9.93M | Sell |
392,264
-40,457
| -9% | -$1.02M | 0.14% | 94 |
|
|
2023
Q1 | $11.2M | Buy |
432,721
+42,435
| +11% | +$1.14M | 0.16% | 92 |
|
|
2022
Q4 | $9.23M | Hold |
390,286
| – | – | 0.12% | 101 |
|
|
2022
Q3 | $9.89M | Sell |
390,286
-25,826
| -6% | -$906K | 0.14% | 99 |
|
|
2022
Q2 | $13.8M | Buy |
416,112
+52,896
| +15% | +$2.25M | 0.2% | 98 |
|
|
2022
Q1 | $26.2M | Hold |
363,216
| – | – | 0.3% | 87 |
|
|
2021
Q4 | $33.4M | Buy |
363,216
+147,310
| +68% | +$17.6M | 0.34% | 82 |
|
|
2021
Q3 | $27.4M | Sell |
215,906
-42,042
| -16% | -$6.12M | 0.28% | 94 |
|
|
2021
Q2 | $42.9M | Buy |
257,948
+3,371
| +1% | +$546K | 0.42% | 74 |
|
|
2021
Q1 | $46.3M | Buy |
254,577
+44,225
| +21% | +$10.3M | 0.49% | 64 |
|
|
2020
Q4 | $42.1M | Buy |
210,352
+88,998
| +73% | +$18.1M | 0.48% | 60 |
|
|
2020
Q3 | $26.6M | Sell |
121,354
-29,945
| -20% | -$6.34M | 0.37% | 76 |
|
|
2020
Q2 | $28.9M | Sell |
151,299
-49,936
| -25% | -$8.75M | 0.41% | 60 |
|
|
2020
Q1 | $31.2M | Sell |
201,235
-548,810
| -73% | -$63.8M | 0.6% | 46 |
|
|
2019
Q4 | $62.8M | Sell |
750,045
-389,012
| -34% | -$29.6M | 1% | 33 |
|
|
2019
Q3 | $77.1M | Sell |
1,139,057
-295,955
| -21% | -$19.5M | 1.43% | 18 |
|
|
2019
Q2 | $95.3M | Buy |
1,435,012
+60,718
| +4% | +$3.54M | 1.63% | 15 |
|
|
2019
Q1 | $76.4M | Buy |
1,374,294
+300,455
| +28% | +$18.3M | 4.2% | 5 |
|
|
2018
Q4 | $53.2M | Buy |
1,073,839
+487,319
| +83% | +$29.8M | 3.5% | 7 |
|
|
2018
Q3 | $50.6M | Buy |
586,520
+16,410
| +3% | +$1.17M | 3.21% | 6 |
|
|
2018
Q2 | $33.1M | Buy |
570,110
+54,416
| +11% | +$2.66M | 2.82% | 8 |
|
|
2018
Q1 | $20.8M | Buy |
515,694
+468,694
| +997% | +$17.7M | 2.06% | 13 |
|
|
2017
Q4 | $1.64M | Hold |
47,000
| – | – | 0.17% | 89 |
|
|
2017
Q3 | $1.56M | Buy |
47,000
+24,500
| +109% | +$803K | 0.16% | 92 |
|
|
2017
Q2 | $781K | Buy |
22,500
+2,500
| +13% | +$72.8K | 0.09% | 113 |
|
|
2017
Q1 | $500K | Buy |
+20,000
| New | +$416K | 0.07% | 122 |
|
Other funds holding TDOC
RCMNY
Bellevue Group's TDOC Position: Q3 2024 in Review
Bellevue Group sold out of Teladoc Health (TDOC) in Q3 2024, closing a stake of 272,798 shares — an estimated $2.67M sold.
Bellevue Group first reported a position in TDOC in Q1 2017 and held it in 30 quarters. The position peaked at $95.3M in Q2 2019. 365 funds tracked by Wall St. Rank hold TDOC as of Q3 2024.
- Bellevue Group reported no remaining Teladoc Health position as of Q3 2024 after selling out during the quarter.
- Bellevue Group sold 272,798 Teladoc Health shares in Q3 2024, an estimated $2.67M.
- Bellevue Group first reported a position in Teladoc Health in Q1 2017 and held it in 30 quarters.
- Bellevue Group's Teladoc Health position peaked at $95.3M in Q2 2019.
- 365 funds tracked by Wall St. Rank held Teladoc Health as of Q3 2024.
Based on Bellevue Group's 13F filing for Q3 2024, filed 14 Nov 2024.